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ABSTRACT 
 
The development of therapeutic strategies for skeletal muscle diseases, such as physical injuries and 
myopathies, depends on the knowledge of regulatory signals that control the myogenic process. The 
obestatin/GPR39 system operates as an autocrine signal in the regulation of skeletal myogenesis. Using 
a mouse model of skeletal muscle regeneration after injury and several cellular strategies, we explored 
the potential use of obestatin as a therapeutic agent for the treatment of trauma-induced muscle injuries. 
Our results evidenced that the overexpression of the preproghrelin, and thus obestatin, and GPR39 in 
skeletal muscle increased regeneration after muscle injury. More importantly, the intramuscular injection 
of obestatin significantly enhanced muscle regeneration by simulating satellite stem cell expansion as 
well as myofiber hypertrophy through a kinase hierarchy. Added to the myogenic action, the obestatin 
administration resulted in an increased expression of VEGF/VEGFR2 and the consequent 
microvascularization, with no effect on collagen deposition in skeletal muscle. Furthermore, the 
potential inhibition of myostatin during obestatin treatment might contribute to its myogenic action 
improving muscle growth and regeneration. Taken together, our data demonstrate successful 
improvement of muscle regeneration, indicating obestatin is a potential therapeutic agent for skeletal 
muscle injury and would benefit other myopathies related to muscle regeneration. Ac
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INTRODUCTION 
 
Responding to injury, skeletal muscle undergoes an orchestrated process in which the activation of 
various cellular and molecular responses result in the reorganization of innervated, vascularized 
contractile muscle. This regenerative activity takes place in three sequential overlapping phases: 1) the 
inflammatory response; 2) the activation, differentiation, and fusion of satellite stem cells, the myogenic 
progenitors localized between the basal lamina and the muscle fiber membrane; and 3) the maturation 
and remodeling of newly formed myofibers (1). The necrosis of damaged muscle fibers is the initial step 
corresponding to the first stage of muscle degeneration. This event is initiated by dissolution of the 
myofiber sarcolemma, which leads to increased myofiber permeability. Myofiber necrosis also activates 
the complement cascade and induces inflammatory responses. Following to the inflammatory responses, 
chemotactic recruitment of circulating leukocytes occurs at the local sites of damage (2). The first 
inflammatory cells to infiltrate the damaged muscle are the neutrophils, which are sequentially followed 
by two distinct subpopulations of macrophages, which invade the injured muscle and become the 
predominant inflammatory cells (3,4). A highly orchestrated regeneration process follows the muscle 
degeneration stage. Upon exposure to signals from damaged environment, satellite cells exit their 
quiescent state and start proliferating. Activated satellite cells give rise to a transient amplifying 
population of myogenic precursor cells that undergo several rounds of division before migrating to the 
site of damage to enter terminal differentiation, fusing to existing damaged fibers or with one another to 
form de novo myofibers (1). Furthermore, satellite cells also possess the ability to undergo self-renewal 
to restock the quiescent satellite cell population, thus allowing tissue homeostasis and multiple rounds of 
regeneration during their life span (1). At molecular level, a broad spectrum of signals orchestrates the 
activation, proliferation and differentiation of the quiescent satellite cells. These signals include, among 
others, hepatocyte growth factor (5), insulin-like growth factors (6), myostatin (7), vasopressin (8) and 
Wnts (10). These signaling molecules determine the intracellular pathways that converge on a series of 
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transcription and chromatin-remodeling factors delineating the gene and microRNA expression program 
that delimit myogenic identity (1, 11). Myogenic transcription factors are organized in hierarchical gene 
expression networks that are spatiotemporally activated or inhibited during lineage progression (1, 12). 
In particular, the muscle regulatory factors (MRF), MyoD, Myf5, myogenin, and MRF4 are essential for 
myoblast lineage commitment. The MRF, in conjunction with other transcriptional regulators, induce the 
expression of muscle-specific genes, such as myosin heavy chain (MHC), that determine terminal 
myogenic differentiation (1, 12).  
 
Much attention has been recently given to the understanding of the molecular and cellular mechanisms 
underlying skeletal muscle regeneration in different contexts, since such knowledge will ultimately 
facilitate the development of new treatments for myopathies (1, 11). One theoretical approach is the use 
of autocrine/paracrine signals in a therapeutic setting to help the replacement of damaged or degenerated 
muscle tissue. In this context, we have recently reported that obestatin, a 23-amino acid peptide derived 
from a polypeptide called preproghrelin, is involved in muscle regeneration, exerting an autocrine 
function to control the myogenic differentiation program (13). Obestatin is expressed in healthy skeletal 
muscle, and this expression is strikingly increased upon muscle injury. In vitro, obestatin is coordinately 
up-regulated during the early stages of myogenesis, and its level remains sustained throughout terminal 
differentiation. Functionally, blocking obestatin during myogenesis induces a decrease in myogenic-
associated markers, such as myogenin and MHC, a process requiring the G protein-coupled receptor 
GPR39. Exogenous obestatin stimulation of undifferentiated myoblasts promotes the mitogenic activity 
and the migration function of myoblasts. Additionally, this peptide increases myogenic differentiation, 
leading to a rise of the fusion index. These results are endorsed by in vivo testing of skeletal muscles 
obtained from male rats under continuous subcutaneous infusion of obestatin. This peptide up-regulates 
of the hierarchy of transcription factors involved in the control of the different stages of the myogenic 
program: Pax7, Myf5, MyoD, myogenin and Myf6. Notably, obestatin increases the expression of 
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VEGF and its receptor isoform VEGFR2 for the potential regulation of the angiogenic process in 
skeletal muscle tissue. This latter effect is important for the potential regulation of the angiogenic 
process in the skeletal muscle providing the needed vascularization for developing skeletal muscle.  
 
The ability of obestatin to drive different stages of the myogenic program suggests its potential use as a 
therapeutic agent for the treatment of trauma-induced muscle injuries or skeletal muscle myopathies. In 
the present study, we used an established model of skeletal muscle regeneration after injury to determine 
if obestatin, either by modulation of its expression or by exogenous administration, would enhance 
skeletal muscle regeneration after injury. Using several cellular strategies, we also analyzed the 
mitogenic and myogenic capabilities of this peptide and the associated-intracellular signaling pathways.  
 
RESULTS 
 
Overexpression of the obestatin/GPR39 system in vivo enhances muscle regeneration. 
We previously demonstrated that GPR39 is required for the activation of obestatin signaling (13). To 
confirm that obestatin binds to GPR39, we performed a co-immunoprecipitation experiment using 
hemagglutinin (HA)-tagged obestatin (obestatin-HA). The HA tag does not interfere with obestatin 
bioactivity as evidenced by the increased phosphorylation of ERK1/2 and Akt in C2C12 myoblast cells 
(upper panel of Fig. 1a). As Fig. 1a (bottom panel) shows, obestatin-HA co-immunoprecipatated 
specifically with GPR39-GFP, but not with GFP alone. Thus, co-immunoprecipitation experiments 
demonstrated the binding of obestatin to GPR39 in cultured C2C12 myoblast cells. Therefore, we 
investigated the role of the obestatin/GPR39 system in muscle regeneration in vivo, preproghrelin, and 
thus obestatin, was overexpressed by electroporation of a CMV-preproghrelin expression plasmid into 
the TA muscles of 8-weeks-old mice. Freeze injury of the muscle was chosen due to the significantly 
reduced inflammatory response relative to other methods, such as cholera toxin injection. The changes 
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in protein expression were performed at 96-h post-injury, corresponding to the acute phase of 
regeneration, and at 168-h post-injury, when the satellite cells have returned to a quiescent stage. The 
histological analysis of the electroporated muscles with the CMV plasmid revealed no regeneration 
deficit as compared to control electroporations, where an empty vector was electroporated (Fig. 1b). In 
addition, the immunostaining of the TA muscles cryosections, 168-h following electroporation with the 
CMV plasmids, exhibited higher levels of preproghrelin, GPR39 or both (left panels of Fig. 1c and 2a-b, 
respectively). The CMV-preproghrelin electroporated TA muscles exhibited an increase in protein 
expression of Pax7, MyoD, myogenin and embryonic MHC (eMHC; Fig. 1c) at 96- and 168-h time 
points. At the same time points, overexpression of CMV-GPR39 plasmid also resulted in an increase of 
these myogenic markers (Fig. 2a). Notably, the electroporated TA muscles with both CMV-
preproghrelin and CMV-GPR39 plasmid revealed a larger augment of Pax7, MyoD, myogenin and 
MHC (Fig. 2b) at 96- and 168-h time points. Taken together, these results indicate that overexpression 
of preproghrelin and/or GPR39 enhance muscle regeneration, as evidenced by the increase of the 
myogenic markers expression. Nonetheless, the electroporation conditions used also resulted in an injury 
to the muscle, raising the question of whether active regeneration is a direct consequence of the 
obestatin/GPR39 response. 
 
Obestatin enhances muscle regeneration. To address whether the exogenous administration of 
obestatin is capable of stimulating effective regeneration, the dispersal of obestatin in tissue was 
assessed. Obestatin-HA (300 nmol/kg body-weight) was directly injected into the TA muscles of 2-
month-old mice (n=5) and myofibers were visualized using immunosating for the HA-tag present 30 
min after administration (Fig. 3a). The proportion of HA-positive fibers in TA muscles ranged from 80 
to 90% in distal zone from the injection site. Importantly, following intramuscular delivery, pAkt(S473) 
was present throughout the muscle and not purely localized at the injection site. The number of HA-
positive fibers in the contralateral muscles from the HA-obestatin-treated mice (n = 5) did not show HA-
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positive fibers (≤1%), thus there was no evidence of significant systemic transfer of obestatin from the 
injected side (Fig. 3a). After the dispersal in tissue was evaluated, obestatin (300 nmol/kg body-weight) 
or vehicle (PBS) was directly injected into the TA muscles of 2-month-old mice (n=35/group) following 
freeze injury. The histological analysis (Fig. 3a) revealed that the treated-to-control ratios of 
regenerating fiber (i.e., with centrally located nuclei) cross-section areas were 62 and 28% larger in 
obestatin-treated mice (324±29 and 755±42 µm2) than in control mice (199±22 and 588±88 µm2) at 96- 
and 168-h after injury, respectively (Fig. 3c). At 240-h post-injury, cross-section area analysis revealed a 
significant increase, as compared to control, in the percentage of myofibers of larger area (Fig. 3d): 24% 
vs. 3% of fibers in a range between 4-3x103 µm2, 56% vs. 39% between 2-1x103 µm2, and 18% vs. 56% 
between 1-0.5x103 µm2. This pronounced increase of regenerating in obestatin-treated muscle was 
concomitant with significant increases, as compared to control, in the protein expression of Pax7, 
MyoD, myogenin and eMHC for the time tested (Fig. 3e-i). To confirm the eMHC up-regulation during 
muscle regeneration, immunofluorescence analyses were performed on cryosections of freeze-injured 
TA fixed 96-h post-injury (Fig. 3j). In the control TA-muscle, eMHC was expressed at detectable levels 
in regenerating fibers, of smaller size than the intact fibers (Fig. 3j, left). By contrast, eMHC was 
markedly up-regulated in the obestatin-treated TA muscles (Fig. 3j, right). The number of myonuclei per 
myofiber was significantly increased by 91% in the obestatin-treated (481±19 cells per muscle section) 
compared to the control TA muscles (251±17 cells per muscle section) at 240-h after injury (Fig. 4a). 
Furthermore, we analyzed the serum levels of creatine kinase (CK), a skeletal muscle enzyme released 
during fiber degeneration (14), at 96-h post-injury. In this time-window, treatment with obestatin 
reduced the CK levels with respect to those observed in untreated injured-control animals, suggesting a 
decrease in the level and severity of muscle damage (Fig. 3k). Taken together, these data demonstrate 
that obestatin delivered by intramuscular injection markedly enhances regenerative capacity, as achieved 
by up-regulation of the expression of specific myogenic factors, the significantly increased size of the 
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regenerating myofibers, the muscle fiber growth, the increased myonuclei addition, and the decreased 
serum CK levels.  
 
Obestatin enhances satellite cell activation after muscle injury. Based on the up-regulation of 
Pax7 expression, a specific satellite cells marker (1), in the obestatin-treated TA muscles, satellite cells 
were quantitated in TA muscle sections 96-h post-injury (Fig. 4b). The satellite cells density in the 
obestatin-treated TA muscles harbored ~2.3-fold more Pax7+ cells per section (427±7 cells per muscle 
section) than the control TA muscles (189±12 cells per muscle section) at 96-h after injury. In addition, 
satellite cell number normalized to myofiber length (myofibers isolated from the neighboring area of the 
injured zone) harbored 2.2-fold more Pax7+ cells in the myofibers obtained from the obestatin-treated 
than in the control muscles (Fig. 4c). The elevated number of the Pax7+ cells implies that satellite cells 
underwent enhanced proliferation during muscle regeneration. To ascertain this possibility, the 
expression of Ki67 and Cyclin D1 was evaluated at 96-h after injury. The elevated protein level of Ki67, 
2.3-fold higher in the obestatin-treated than in the control TA muscles (Fig. 5a), implies an enhanced 
proliferation at 96-h after muscle injury. Added to this fact, the elevated protein expression of Cyclin 
D1, 2.2-fold higher in obestatin-treated than in control TA muscles, demonstrated enhanced proliferation 
during regeneration (Fig. 5b). Taken together, these data demonstrated that obestatin enhances satellite 
cell proliferation during the early stages of muscle regeneration.  
 
Muscle force analysis. Present results demonstrated that obestatin induced repair and growth by 
stimulating both satellite cell expansion and myofiber hypertrophy. An unanswered question was 
whether or not the obestatin-treated muscles generate higher specific forces than control muscles under 
this protocol. To address this question, the force generated by TA muscles from obestatin-treated mice 
was measured. Mean twitch and tetanic force of normal TA were respectively 0.21 and 1.36 N (Fig. 5a 
and b, respectively). Mean twitch and tetanic force were fewer 10 days after the induction of injury as 
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the means were 0.16 and 0.94 N, representing a 24 and 34% loss of force, respectively. However, 
despite an improvement of fiber regeneration with obestatin, no difference in mean twitch and tetanic 
force was observed between vehicle- and obestatin-treated TA. The lack of a better functional recovery 
with obestatin suggests that functional recovery takes longer than 10 days, or more likely that by 10 days 
the neuromuscular junctions are still not fully functional and this is important because TA contractions 
were elicited by stimulating the peroneal nerve. 
 
Obestatin affects the essential network for regenerating muscle fiber growth. The 
obestatin-treated-to-control ratios of VEGF and VEGF-R2 protein levels were 130 and 80% higher in 
obestatin-treated than in control TA muscles at 96-h after injury, respectively (Fig. 6c and d). The vessel 
counting, evaluated as isolectin+ per myofiber, showed differences in capillary density in the obestatin-
treated (1.5±0.06) compared to control TA muscles (0.5±0.01) at 96-h post-injury (Fig. 6e). These data 
indicated that obestatin contributed to the restoration of the VEGF/VEGF-R2 tissue levels. Of note, 
there was no significant elevation of collagen 12 (Col12) in obestatin-treated TA muscles at 96-h 
and 240-h after injury (Fig. 6f, upper panel). This result was supported by Heidenhain's AZAN 
trichrome staining of the muscle sections 240-h after injury (Fig. 6f, lower panel). This fact indicated 
that fibrosis is not enhanced during regeneration in the obestatin-treated muscles and did not contribute 
to the increased size of the regenerated muscle. On the other hand, the myostatin protein levels, 
measured as the precursor latency-associated peptide (LAP) and dimer, were respectively 20, 30 and 
60% lower in the obestatin-treated than in the control TA muscles at 96-h after injury (Fig. 6g), which 
corroborated the obestatin role on muscle regeneration and growth.  
 
Obestatin enhances myogenic cell proliferation. Obestatin showed a marked enhancement of 
the regeneration process, an effect probably dependent on myoblast proliferation or differentiation. To 
ascertain this possibility, the mitogenic action of obestatin was explored by dose-effect experiments 
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performed on cultured C2C12 myoblasts treated with a range of obestatin concentrations (0.1–100 nM) 
in GM (proliferating conditions; Fig. 7a). The maximal effect in the cell number was observed at 5 nM 
obestatin (~2.4-fold). During the differentiation process, the immunoblot analysis of Ki67, p57 and p21 
revealed elevated protein expression when compared the obestatin-treated cells (DM+5 nM obestatin) 
with the control cells (DM; Fig. 7b). At 24-h, Ki67 showed maximal expression levels, followed by an 
increase in the expression of p57 and p21, reflecting growth arrest to promote cellular differentiation. In 
fact, the protein levels of myogenin and MHC were up-regulated, displaying maximal levels at 72- and 
96-h respectively (Fig. 7b). Of note, both proliferating and myogenic markers displayed normal kinetics 
with enhanced protein levels when compared the obestatin-treated with the control cells.  
 
Obestatin enhances myoblast fusion and hypertrophic growth of myotubes. The 
exogenous administration of obestatin to TA during regeneration enhanced the area and the number of 
myonuclei per myofiber. To investigate whether obestatin in fact stimulated hypertrophic growth, the 
C2C12 myoblasts were first treated with obestatin under DM (Fig. 8a). The myotube areas were 110% 
larger in the obestatin-treated cells (DM+5 nM obestatin; 941±4 µm2) than in the control cells (DM; 
449±3 µm2) at 168-h after differentiation. Moreover, the myotubes were grouped into two categories, 
those with 3 myonuclei and those with 4 or more myonuclei. ~30% of the control myotubes contained 4 
nuclei versus the 73% of the obestatin-treated cells. This effect represents an increase of ~1.93-fold 
respect to the control cells (Fig. 8a). Having shown that obestatin induced hypertrophy with enhanced 
nuclei addition, we assessed whether the administration of obestatin 3 days after the initiation of 
differentiation was responsive to obestatin-induced hypertrophy in culture (Fig. 8b). In this case, the 
myotube areas were ~80% larger in the obestatin-treated cells (DM for 72-h followed by DM+5 nM 
obestatin for 96-h; 736±7 µm2) than in the control cells (DM; 409±6 µm2) at 168-h after differentiation. 
Under these conditions, ~40% of the control myotubes contained 4 nuclei versus the 87% of the 
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obestatin-treated cells.  Furthermore, the myotubes were treated with obestatin after administration of 
cytosine arabinoside (AraC), an inhibitor of DNA replication to abolish the de novo fusion of the 
myoblasts (15). Of note, the obestatin-treated cells displayed ~92% larger myotubes areas (DM for 72-h 
followed by DM+AraC (50 µM)+obestatin (5 nM) for 96-h; 853±3 µm2; Fig. 8c) than in the control 
cells (DM; 444±4 µm2) at 168-h. Obestatin treatment led to a ~75% of myotubes containing 4 nuclei 
versus the 33% in the control cells. The immunoblot analyses revealed no differences in myogenin and 
MHC levels between both groups: DM+obestatin and DM+AraC+obestatin (Fig. 8d). Taken together, 
these data showed that obestatin exerted a bidirectional role within the myotube, controlling the 
myoblast recruitment to fuse and the growing volume. 
 
Obestatin controls myogenesis by regulating Akt, ERK1/2, p38 and CAMKII activity. To 
establish the molecular events activated by obestatin to drive the myogenic process, the activity of 
Akt/mTOR signaling was analyzed in differentiating C2C12 cells during 168-h (Fig. 9a). The obestatin 
treatment (5 nM) resulted in markedly elevated levels of phosphorylated Akt [pAkt(S473)] and its 
downstream target S6K1 [pS6K1(S371)] during the myogenesis. Despite the increased Akt activity 
under the obestatin treatment, lower levels of pFoxO1(T24) and pFoxO3a(T32) observed in the 
obestatin-treated cells than in the control cells (DM). Obestatin increased ERK1/2 activity 
[pERK1/2(T202/Y204)] in the early steps of the differentiation program. Strikingly, obestatin markedly 
elevated the levels of phosphorylated p38 [pp38(T180/Y182)] during the differentiation. The 
phosphorylation levels of c-Jun [pc-Jun(S63)] showed no significant differences following the obestatin 
treatment compared to the control cells. By contrast, the phosphorylation pattern of CAMKII 
[pCAMKII(T286)] showed clear differences under the obestatin treatment. A gradual increase of 
pCAMKII(T286) was observed in the control cells, reaching maximal levels at 168-h. Under obestatin 
treatment, the maximal level was showed at earlier time points, 12-48 h, to decline to basal 
phosphorylation after 48-h. In regenerating TA muscle, obestatin treatment resulted in a robust 
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activation of Akt and S6K1 at 96-h after injury (Fig. 10a). Other signaling components, ERK1/2, 
FoxO1, FoxO3a, p38, c-Jun and CAMKII, did not show showed significant differences in 
phosphorylation at this time point. Together, a kinase hierarchy determined the action of obestatin in an 
analogous manner to the myogenic transcription factors.  
 
Obestatin regulates myogenesis by limiting IGFR/IRS1 activity. Obestatin signals to activate 
the Akt/mTOR pathway through cross-talk with tyrosine kinase receptors, i.e. EGFR (16). To investigate 
the possibility that obestatin was indirectly activating the Akt/mTOR pathway through IGFR, the 
activation of IFGR [measured as pIGFR(Y1316)], was examined in differentiating C2C12 cells during 
168-h (Fig. 8b). Obestatin showed to increase the level of pIGFR(Y1316) at early time points (12-48-h). 
However, under these conditions there was a substantial increase of the IRS-1 phosphorylation at 
S636/639 [pIRS-1(S636/639)], sites shown to inhibit PI3K binding to IRS-1 and consequent activation 
of Akt-associated IGFR signaling (Fig. 9b) (17). In regenerating TA muscle, obestatin treatment showed 
to enhance the levels of pIGFR(Y1316) and pIRS-1(S636/639) at 96-h after injury (Fig. 10b). Therefore, 
obestatin action on Akt/mTOR pathway is independent of IGFR/IRS1 activity.  
 
DISCUSSION 
 
The principal finding of this study is that obestatin increases muscle regeneration after skeletal muscle 
injury. Our results have evidenced that: 1) the overexpression of the obestatin/GPR39 system in skeletal 
muscle enhanced muscle regeneration after muscle injury; 2) the intramuscular injection markedly 
enhances muscle regeneration, as evidenced by the up-regulation of the expression of the specific 
myogenic factors (Pax7, MyoD, myogenin) and eMHC, the noteworthy decrease of serum CK levels, 
and, more importantly, the significant increase of the myofiber size and the number of myonuclei per 
myofiber; 3) the up-regulation of the specific satellite cells marker Pax7, associated to the increased 
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number of activated satellite cells (Pax7+) per myofiber, demonstrated the actions of obestatin on 
satellite cells; 4) the effective action was due to a specific regulation of this peptide on the different 
stages affecting the myogenesis: proliferation, migration, fusion and myofiber growth; 5) added to the 
myogenic action, obestatin administration resulted in an increased expression of VEGF/VEGFR2 and 
microvascularization, with no significant effect on collagen deposition in developing skeletal muscle; 6) 
the potential inhibition of myostatin might contribute to the myogenic action improving muscle growth 
and regeneration; and, 7) the myogenic actions of obestatin were coordinated by a kinase hierarchy 
determined by the ERK1/2, CAMKII, Akt and p38 axis. These findings unveil a role for obestatin in the 
regulation of satellite cell-mediated muscle regeneration and identify obestatin as a potential therapeutic 
target for a variety of conditions related to muscle regeneration. 
 
In response to obestatin, the hierarchy of transcription factors regulating progression through the 
myogenic lineage was clearly increased. This is endorsed by the increased expression of myogenic 
regulator factors, Pax-7, MyoD, and myogenin, demonstrating the myogenic potential for this peptide 
when it is administrated into injured muscle. The up-regulation of Pax7 expression is indicative of a 
control on satellite cell activation to enhance myogenic specification and/or to induce self-renewal (18). 
It is known that this transcription factor is maintained in satellite cells and proliferating myoblasts but it 
is down-regulated before differentiation (1, 19). Indeed, satellite cell number increased on muscle 
sections as well as in myofibers obtained from obestatin-treated muscles at 96-h after injury. The 
increased satellite cell proliferation was concomitant with an enhanced tissue expression of Ki67, a 
proliferating cell marker, and Cyclin D1, a well-known effector of the G1 to S cell cycle phase 
transition, at 96-h after injury, although it does not exclude the implication of any other cell type that is 
proliferating. Added to the increasing Pax-7 expression level, obestatin-treated mice showed up-
regulation of MyoD expression. MyoD is an important determinant of myogenic differentiation, 
although MyoD expression does not always ensure myogenic commitment. It was found that the ratio of 
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Pax7/MyoD activities becomes critical for the control of satellite cell fate (reviewed in 1). However, the 
induction of myogenin expression, which primarily depends on MyoD (1), denoted the initiation of 
terminal differentiation. This program dictates the differentiation process driving the transformation 
from individual proliferating myogenic cells to myofibers. This transition was supported by the up-
regulation of proteins such as MHC. Further support was demonstrated by the augmentation of the 
myogenic markers by in vivo overexpression of preproghrelin during muscle regeneration. However, it 
would implicate the contribution of the preproghrelin-derived peptides, ghrelin, des-acyl ghrelin and 
obestatin (13, 20, 21), as pro-myogenic signals. Overexpression of GPR39 resulted in up-regulation of 
the myogenic cascade, a result that supports the autocrine role of obestatin to trigger the myogenic 
differentiation program (13). Importantly, in vivo co-overexpression of GPR39 and preproghrelin during 
muscle regeneration resulted in a larger enhancement of the myogenic markers compared to that 
obtained from GPR39 or preproghrelin overexpression alone. These findings emphasize the remarkable 
role of the obestatin/GPR39 system into the remodeling of damaged fibers following injury. It should be 
highlighted that despite electro-transfer of DNA demonstrated to be an efficient method to deliver genes, 
the results could be improved by viral gene transfer whose effectiveness is clearly superior.  
 
At late stage of muscle regeneration, obestatin treatment increased the cross-sectional area of the newly 
formed muscle fibers. Another effect of obestatin favoring muscle regeneration was the increased 
density of myonuclei in regenerating fibers. This duality might be interpreted as a result of mitotic 
expansion of satellite cells to differentiate and repair the tissue reestablishing homeostasis. Given that 
myonuclei are post-mitotic, the necessity of expansion of committed satellite cells, myoblasts, for 
muscle hypertrophy was determined under obestatin stimulation 3-days after C2C12 differentiation, or 
in AraC-treated cultures. Under these conditions, the growth response and myonuclei accretion induced 
by obestatin was not altered. Furthermore, the protein expression of myogenin and MHC was not 
affected by AraC treatment. Thus, the hypertrophic response to obestatin was not associated with the 
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addition of new myonuclei via proliferation and further fusion. Added to this fact, immunoblot analyses 
revealed normal, although enhanced, kinetics of myogenin or MHC expression ruling out accelerated 
kinetics of the differentiation program. This scenario proposes that the hypertrophy or fusion response to 
obestatin is not consequence of accelerated kinetics of differentiation or enhanced myoblast 
proliferation. The result that hypertrophy response was independent of myoblast proliferation is not 
without precedent. Specifically, it was reported that hypertrophy resulting from Wnt7a stimulation 
occurred without the enhancement of myoblast proliferation or accelerated kinetic of differentiation 
(15). It should be considered that hypertrophy is strongly associated to the level of Akt/mTOR/S6K1 
activation, a pathway activated by obestatin during the differentiation program and the diverse stages 
comprised in the process of skeletal muscle regeneration (22, 23). This pathway controls mechanisms of 
protein synthesis at several stages (e.g., translation capacity, translation efficiency) through the increase 
of specific mRNAs translation, which results in myotubes and fiber enlargement.  
 
In addition to its myogenic action, obestatin also regulated the expression of factors that define the 
regenerative microenvironment responsible for stimulating and coordinating skeletal muscle repair. In 
this sense, obestatin increased the expression of VEGF and its receptor isoform VEGF-R2 during muscle 
regeneration. Besides being described as a myogenic factor (24), VEGF was shown to stimulate muscle 
healing by promoting angiogenesis (25, 26). Precisely, the VEGF produced by differentiating myocyte 
provides the needed vascularization for the developing skeletal muscle. Our results further indicated that 
obestatin-treated injured muscles increased capillary density being indicative of enhanced 
microvascularization. These new developed capillaries sprout out from peripheral surviving capillaries, 
helping to provide the injured area with oxygen and substrates aiding in the regenerative process. Added 
to vascularization, obestatin reduced the expression of myostatin, a highly conserved transforming 
growth factor-family member (27). Myostatin regulates muscle growth through a direct inhibition of 
the proliferation and differentiation of the satellite cells (28, 29). Although myostatin inhibits myocyte 
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proliferation and differentiation, it regulates muscle fibrosis through the stimulation of muscle 
fibroblasts and the expression of extracellular matrix proteins, such as collagen (30, 31). In this sense, it 
is important to note that obestatin treatment did not increase collagen deposition in regenerating muscle 
ruling out a fibrotic response. Whereas obestatin directly stimulates myogenesis, it is logical to postulate 
that this effect might be mediated partially through inhibition of myostatin. Furthermore exits the 
possibility that the inhibition of myostatin contributes to the regulation of extracellular matrix proteins. 
This is supported by the finding that myostatin stimulates collagen production of muscle fibroblasts (31). 
Thus obestatin regulates the new vessel formation and/or remodeling of the preexisting vasculature 
under the control of local pro-angiogenic program, such as VEGF/VEGFR2 system, representing an 
integral component of muscle tissue remodeling which control the extent of the injury preventing a 
deleterious microenvironment characterized by fibrosis. 
 
One of the most remarkable observations from this study was that obestatin has multiple functional 
properties associated to the skeletal muscle regeneration, and its capability to stimulate proliferation, 
differentiation, fusion and hypertrophy response is under regulation of a kinase hierarchy. The cell cycle 
arrest and the onset of differentiation are orchestrated by p21and p57. In our study, the expression of p57 
and p21 is linked to an absence of cell cycle progression, since we observe no overlap with Ki67. MyoD 
has been suggested to be a direct regulator of p21, thus controlling the cell cycle exit during adult 
muscle differentiation (32). It has also been shown that p57 interacts and stabilizes MyoD to promote 
muscle differentiation (33, 34). In this way, interactions between cyclin-dependent kinase inhibitors 
essential for myogenic growth and MRFs orchestrate the proliferation, specification and differentiation 
of muscle progenitor cells (35, 36).  In the C2C12 differentiating myoblasts, obestatin enhanced ERK, 
CAMKII, Akt, and p38 activities. These pathways displayed the ability to execute different stages of the 
regeneration program. On one side, ERK1/2 belongs to a well-defined pathway, which is critical for 
cellular proliferation and migration (37). In the context of obestatin-induced activity, ERK initially 
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decreased with myoblast differentiation, which is necessary for differentiating myoblasts to overcome its 
inhibitory effect. Indeed, ERK was showed to inhibit differentiation by preventing the nuclear 
accumulation of members of the myocyte enhancer factor-2 (38), and the expression of certain myogenic 
factors, including MyoD (39) and the CDK inhibitor p21 (40). In the case of CAMKII, its signaling 
prevents the formation of MEF2–HDAC complexes by phosphorylation of HDAC4/HDAC5, promoting 
a nuclear export of these transcriptional repressors and the rising of MEF2 activity on muscle specific 
genes such as MyoD and myogenin (41). In particular, the earlier activation of CAMKII by obestatin 
(≥12-h) compared with that of control (≥144 h), is not consistent with a premature expression of 
myogenin in response to obestatin compared with control. This piece of information reveals additional 
roles for CAMKII in the obestatin-regulated signaling during differentiation. Thus it is possible to 
speculate about the role of this kinase in the regulation of cell cycle, and hence, the control of the 
proliferative step during differentiation, based on its function on G2/M and the metaphase-anaphase 
transition described for it (42). Regarding the Akt pathway, this route has emerged as a critical signaling 
node within myogenic program. The consequences of Akt activation include diverse responses, ranging 
from primarily metabolic functions such as glucose transport, glycolysis, glycogen synthesis, and the 
suppression of gluconeogenesis to protein synthesis, increased cell size, cell-cycle progression and 
apoptosis suppression (43). Obestatin showed to increase the levels of activated Akt during myogenesis. 
The wide range of cellular functions mediated by this kinase is related to the different Akt isoforms. 
Thus, Akt1 was described to be essential in early differentiation leading to cell cycle progression (44). 
By contrast, Akt2 triggers myoblast cell cycle exit and drives differentiation determining myotube 
maturation (44). Following to the commitment in the myogenic differentiation, the hypertrophic muscle 
growth induced by obestatin might be under the regulation of the downstream effectors of the Akt 
pathway, FoxO1 and FoxO3a (22, 45, 46). However, the degree of obestatin-induced phosphorylation of 
FoxO1 and FoxO3a remained lower than in the untreated cells, pointing to a pivotal role for the S6K1-
dependent pathway. p38 kinase activity increased over the course of differentiation under obestatin 
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treatment, a fact that fit well with the established role of this kinase in the cell cycle arrest and full 
myoblasts differentiation through the control of muscle-specific gene expression (47, 48). Our results 
further showed that obestatin mediated the cessation of the JNK/cJun proliferation-promoting pathway, 
prerequisite for the commencement of the differentiation program (49). Interestingly, decreased 
activation of the JNK/cJun pathway was concomitant to p38 activation in differentiation-promoting 
conditions under obestatin treatment. The convergence of these pathways at the chromatin level defines 
the mechanism for integration of mitogenic and myogenic signals to direct the transition from 
quiescence to terminal differentiation (50). Therefore, obestatin action is a highly coordinated process in 
which various signaling pathways converge to activate a specific gene expression program associated to 
each stage of the myofiber formation process.  
 
Once obestatin activates GPR39, two routes are triggered in parallel: 1) sequential activation of Gi, 
PI3K, novel PKCε and Src and the subsequent ERK1/2 activation; and 2) a β-arrestin 1-mediated 
signaling pathway that involves the recruitment of Src to the -arrestin 1 scaffolding complex, and thus 
Akt phosphorylation (16, 51). In this way, Akt activation is switched by cross-activation of receptor 
tyrosine kinases, i.e. EGFR, in which Src acts to activate matrix metalloproteinases to initiate the 
proteolytic release of the EGF-like ligands onto the cell surface, which later bind to EGFR. Based on 
this cross-activity, one might wonder whether obestatin-associated Akt activity, such as skeletal muscle 
hypertrophy, might simply be switched by cross-activation of IGFR, one of the main regulators of 
muscle mass by stimulating the Akt/mTOR pathway (22). Indeed, obestatin transactivated IGFR, a 
process that leads to activation of Akt by stimulating the IRS-1/PI3K pathway. Interestingly, there was a 
substantial increase of the IRS-1 phosphorylation at S636/639, sites shown to inhibit PI3K binding to 
IRS-1 (17) and thus the Akt/mTOR signaling associated to IGFR. At present, it is well documented that 
S6K1 is implicated in a negative feedback loop on IRS-1 S636/639 phosphorylation to suppress PI3K 
signaling (17, 52, 53). Consistent with this finding, our results showed that the increase of pS6K1(T389) 
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levels paralleled to the enhancement in pIRS-1(S636/639). Under these conditions, the S6K1 activation 
impaired IRS-1/PI3K signaling decreasing the Akt associated signaling to IGFR. Despite the cross-
activation of IGFR, the negative feedback loop from S6K1 to IRS-1 rules out the implication of 
IGFR/IRS-1 system in the obestatin-induced Akt/mTOR signaling. Therefore, obestatin-associated Akt 
kinase activity, i.e. myogenesis or muscle growth, is independent of IGFR/IRS1 pathway.  
 
In summary, our findings provide compelling evidence for the use of obestatin as a therapeutic approach 
to stimulate muscle regeneration. On a first consideration, the current study raises the possibility of a 
new strategy for skeletal muscle repair by local administration into the injured site. It is important to 
note that sports-related injuries can pose challenging problems in sport medicine and traumatology. The 
best treatment for the most common acute muscle injuries has not been clearly defined yet, and the 
recommended treatment regimens are mostly conservative and routine. Additionally, to develop superior 
treatments for treating muscle pathologies, an interesting area has arisen focusing on the modulation of 
satellite cells function through the identification of autocrine factors and the related molecular pathways 
that govern their activation and proper differentiation. The ability of the obestatin/GPR39 system to 
activate stem cell expansion and muscle growth combined to its role on vascularization and fibrosis 
makes obestatin a promising candidate, if it has no deleterious side effect, Ideally, this type of therapy 
would activate satellite cells to enhance their regenerative potential avoiding the exhaustion of such 
cells. Although this mode of action does not treat the genetic basis of the pathological background 
associated to some of the muscle pathologies, it might be sufficient to maintain a stable level of 
regeneration and reduce the severity of certain symptoms. Furthermore, endogenous repairing factors are 
also required for combinatorial therapies with gene or cell-based strategies. Thus, future investigations 
in the development of these simple therapeutic approaches, targeting satellite cells, can offer new and 
important possibilities for the amelioration of skeletal muscle diseases. 
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MATERIALS AND METHODS 
 
Materials. Rat/mouse obestatin was obtained from California Peptide Research (Napa, CA, USA). 
Hemagglutinin (HA)-tagged obestatin (obestatin-HA) was obtained from Biomedal (Sevilla, ES). 
Antibodies used are listed in Table S1. All other chemical reagents were from Sigma Chemical Co. (St. 
Louis, MO, US). 
 
Mice and animal care. This study used 8-weeks-old female Swiss mice (30 g). Mice were housed in 
12 hours light/12 hours dark cycles with free access to standard mice chow diet and water. All mice 
were maintained inside animal care facility and the experiments were performed in accordance with 
University of Sapienza (Rome, Italy) and University of Santiago de Compostela (Santiago de 
Compsotela, Spain) guidelines for animal handling and care. For the experiments at the University of 
Ottawa (Ottawa, Canada), all procedures were approved by the Animal Care Committee of the 
University of Ottawa according to guidelines of the Canadian Council for Animal Care (CCAC). 
 
Freeze-induced muscle injury and obestatin dosing. The experimental protocol used in the 
present work was previously optimized and validated by Moressi V et al. (14). Under anesthesia, the 
hindlimbs of the mice were shaved and both tibialis anterior muscles (TA) were exposed via a 1-cm-
long incision in aseptically prepared skin overlying the muscle. Traumatic freeze injury was induced by 
applying a 120-mm-diameter steel probe, pre-cooled to the temperature of dry ice (−79°C), to the belly 
of the TA muscle for 10 seconds. After injury procedure, the skin incision was closed using 6-0 silk 
sutures. This procedure induced a focal injury extending distally from the spike of the tibia and 
spreading over approximately one-third of the muscle. The average length and maximal cross-sectional 
area of the lesion sites, evaluated by Evans Blue labeling (14), were 3202±14 µm and 3875789±27501 
µm2, respectively (mean±SEM). Animals were assigned to one of two-matched experimental groups 
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(n=35 per group): 1) Obestatin-treated group; and, 2) control group. Obestatin treatment was performed 
via injection of 20 µL of obestatin solution in PBS [300 nmol/kg body weight (13)] into the target 
muscles each 24 hours (h) during 5 days. Control group was treated with 20 µL of PBS under same 
conditions. Injections were performed twice per muscle inserting the needle of a 0.3 mL/29 gauge 
syringe (Becton, Dickinson and Company, Franklin Lakes, NJ) for 1 mm in the distal part of the muscle, 
in a region that is not taken into account for histological analysis, as it was previously demonstrated 
(14). This procedure did not induce muscle fiber damage, as Evans Blue uptake was not detectable 
following injection in an adult muscle. TA muscles from both groups were excised at indicated time 
points (12-240 hours; n=5 per time point) and processed for immunoblot, immunohistochemistry and/or 
immunofluorescence analyses.  
 
In vivo electroporation. To overexpress preproghrelin and/or GPR39 [mouse preproghrelin 
(GenBank NM_021488.4) and GPR39 (GenBank NM_027677) cDNAs in pCMV6-entry vector were 
from OriGene Tech (Maryland, USA)], the plasmid DNAs or pCMV6 (Mock; Origene; MD, USA) in 
PBS were directly co-injected with 5 µg pcDNA 3.1-SNAP-GFP (transfection marker; kindly provided 
by Prof. Pozzan; University of Ferrara, Italy) into TA of 8-weeks-old female Swiss mice (30 g) followed 
by electroporation. Electroporation was performed before muscle injury by delivering six electric pulses 
of 20 V each (three with the anode placed on the front of the TA, followed by three pulses with inverted 
polarity). A pair of 3×5 mm Genepaddle electrodes (BTX, San Diego, CA) placed on each side of the 
TA muscle was used. The electrodes cover an area corresponding to the majority of the muscle surface 
and, thus, totally overhang the area of injury. This protocol of gene delivery by electroporation 
guarantees stable DNA expression for more than 4 months (8). Mice were sacrificed at 96- and 168-h 
(n=5 per group) after injury.  
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Myofiber isolation. Single myofibers were isolated from TA mucles as previously described (54). For 
in vivo activation of satellite cells, regeneration was induced in the TA after freeze injury and individual 
myofibers were isolated 96-h later from the neighboring area of the injured zone of the TA muscle. 
Immunochemical labeling of myofibers were performed as previously reported (55). 
 
Force measurement. Mice were anaesthetized by intraperitoneal injection of 2.2 mg ketamine/0.4 
mg xylazine/ 0.22 mg acepromazine per 10 g of animal body weight. Mice were put on a heating pad to 
maintain body and muscles at 37°C. The distal tendon of the TA muscle was attached to a FT03 Grass 
Instruments force transducer, which was connected to a Grass physiograph (Model 79D, Grass 
Technologies, Warwick, USA). An output of the polygraph was also connected to a digital data 
acquisition system (KCPI3104, Keithley, USA) to acquire force at a sampling rate of 5 kHz. TA was 
kept moist with a physiological solution containing 118.5 mM NaCl, 4.7 mM KCl, 1.3 mM CaCl2, 3.1 
mM MgCl2, 25 mM NaHCO3, 2 mM NaH2PO4, and 5.5 mM D-glucose continuously gassed with a 
mixture of O2:CO2 (95:5) to maintain a pH=7.4. Contractions were evoked every 100 sec by field 
stimulation using two platinum wires 0.6 cm apart on a short section of the peroneal nerve. The platinum 
electrodes were connected to a Grass S88X stimulator and a Grass SIUV isolation unit (Grass 
Technologies, Warwick, USA). Single twitches were elicited with one 0.3 msec square pulse at 10 V. 
Maximum force was measured during a tetanic contraction with 200 msec train of pulses at 200 Hz.  
 
Cell culture and differentiation. Mouse C2C12 myoblasts were cultured as described by the 
supplier (ECACC, Whiltshire, UK). Briefly, the C2C12 myoblasts were maintained in growth medium 
(GM) containing DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 
100 U/mL streptomycin. For routine differentiation, the cells were grown to 80% confluence and GM 
was replaced with differentiation medium (DM; DMEM supplemented with 2% FBS, 100 U/mL 
penicillin, and 100 U/mL streptomycin) for 7 days unless otherwise stated. 
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Cell transfection and co-immunoprecipitation. To overexpress GPR39 (GFP-tagged) [mouse 
GPR39 cDNAs in pCMV6-AC-GFP was from OriGene Tech (Maryland, USA)], the plasmid DNA or 
pCMV6-AC-GFP (Mock; Origene; MD, USA) were transfected in C2C12 myoblast cells using 
Lipofectomine 2000 according to instructions provided by the manufacturer. The relative percentage of 
GPR39-GFP transfection, expressed as % GFP-positive cells, was 70±7%. Obestatin-HA, obtained from 
Biomedal (Sevilla, ES), was administered to the cells in a final concentration of 5 nM for 2 min. Co-
immunoprecipitation was conducted using Chromotek-GFP Trap beads purchased from Allele 
Biotechnology&Pharmaceuticals according to instruction provided by manufacturer.  
 
Histology and immunofluorescence. Muscle samples were mounted in tissue freezing medium 
(tragacanth paste) and snap frozen in nitrogen-cooled isopentane. The sections, 10 µm thick, were 
mounted on Histobond Adhesion Microslides (Marienfeld, Lauda-Königshofen, DE). For the 
haematoxiline/eosin and Heidenhain's AZAN trichrome stains, serial cryostat sections were stained 
following a standard protocol. Muscle sections for immunofluorescence analysis were permeabilized 
and blocked with PBT [1% Triton X-100, 1% Tween-20, 5% heat inactivated goat serum, 0.2% BSA in 
PBS] for 30 min, and incubated with primary antibodies diluted in PBT overnight at 4ºC, washed with 
PBS and then incubated with a mixture of appropriate secondary antibodies for 45 min at 37ºC. DAPI 
was used to counterstain the cell nuclei (Life Technologies, Invitrogen, Gran Island, NY, US). For 
quantification of regenerating fibers, identified by morphological criteria (i.e. centrally located nuclei), 
and myofiber cross-section area, the cryostat sections were stained with haematoxylin/eosin and five 
randomly chosen microscopic fields from two different sections in each tissue block were examined 
using ImageJ64 analysis software. Quantification of satellite cells in a whole section of TA muscles was 
performed by counting Pax7 positive cells (Pax7+) using ImageJ64 analysis software. At least 4 sections 
from each TA muscle were analyzed and the mean results of sections from each muscle were further 
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calculated as mean value of muscles. Quantification of satellite cells, based on single myofibers, was 
performed by quantitating Pax7+ cells in at least 12 myofibers isolated from the neighboring area of the 
injured zone of the TA muscle. For vessel counting, the total number of isolectin+ vessels 
neightboringand the total number of laminin myofibers were measured for each cross-section. For 
analysis of cultured cells, the C2C12 cells were cultured on coverslips and differentiated into myotubes. 
The intact cells were fixed with 4% buffered paraformaldehyde-PBS, washed, permeabilized and 
blocked with PBT, and then stained with primary antibody diluted in PBT overnight at 4ºC. The cells 
were then washed and incubated with secondary antibody for 45 min at 37ºC. DAPI was used to 
counterstain the cell nuclei (Life Technologies, Invitrogen, Gran Island, NY, US). Five fields from three 
independent experiments were randomly selected for each treatment. The differentiation grade was 
evaluated based on the number of MHC positive cells above total nuclei. The number of nuclei within 
individual myotubes (≥ 2 nuclei) was counted for 20–50 myotubes. The myotubes were grouped into 
two categories, those with 2 to 3 nuclei and those with 4 or more nuclei, and the percentage of the 
myotubes in each category was calculated relative to the untreated cells (20). The digital images of the 
cell cultures were acquired with a Leica TCS-SP5 spectral confocal microscope (Leica Microsystems, 
Heidelberg, DE).  
 
Immunoblot analysis. The tissue or the cell samples were directly lysed in ice-cold RIPA buffer [50 
mM Tris-HCl (pH 7.2), 150 mM NaCl, 1 mM EDTA, 1% (v/v) NP-40, 0.25% (w/v) Na-deoxycholate, 
protease inhibitor cocktail (Sigma Chemical Co, St. Louis, MO, US), phosphatase inhibitor cocktail 
(Sigma Chemical Co, St. Louis, MO, US)]. The lysates were clarified by centrifugation (14,000xg for 15 
min at 4°C) and the protein concentration was quantified using the QuantiProTM BCA assay kit (Sigma 
Chemical Co, St. Louis, MO, US). For immunoblotting, equal amounts of protein were fractionated by 
SDS-PAGE and transferred onto nitrocellulose membranes. Immunoreactive bands were detected by 
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enhanced chemiluminescence (Pierce ECL Western Blotting Substrate; Thermo Fisher Scientific, Pierce, 
Rockford, IL, US).  
 
Creatine kinase activity assay. Serum creatine kinase was assayed using the Enzy-Chrom Creatine 
Kinase Assay Kit (BioAssay Systems) according to the manufacture’s instructions. 
 
Data analysis. All values are presented as mean ± standard error of the mean (SEM). Student t test 
were performed to assess the statistical significance of 2-way analysis. For multiple comparisons, 
ANOVA was employed. P <0.05 was considered as statistically significant (*). 
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FIGURE LEGENDS 
 
Figure 1 Ectopic expression of preproghrelin enhances muscle regeneration. (a) Upper 
panel, immunoblot analysis revealed comparable levels of pERK1/2(T202/Y204) and 
pAkt(S473)  under HA-obestatin stimulation (5 nM, 10 min) to obestatin-treated C2C12 
myoblast cells (5 nM, 10 min). Lower panel, immunoprecipitation analyses using GFP coupled 
beads demonstrated that GPR39-GFP binds obestatin-HA in C2C12 myoblast cells while it 
does not bind GFP alone. (b) Representative histology sections of transfected muscle 96- and 
168-h after electroporation with CMV plasmid in TA. (c) Left panel, fluorescence microscopy of 
GFP (pcDNA 3.1-SNAP-GFP, transfection marker) and immunofluorescence analysis of 
cryosections stained with specific antibodies reactive to laminin and preproghrelin 168-h after 
electroporation with the CMV-preproghrelin plasmid in TA. Right panel, representative 
immunoblots of the mean values from each group of the expression of Pax-7, MyoD, 
myogenin, and eMHC at 96- and 168-h after ectopic expression of preproghrelin. Bottom 
panel, immunoblot analysis of the expression of Pax-7, MyoD, myogenin, and MHC at 96- and 
168-h after ectopic expression of preproghrelin. Protein levels were expressed as fold of 
control obtained from electroporation of CMV plasmid group (n=5/group). Data were expressed 
as mean±SEM obtained from intensity scans. *P <0.05 versus control values. 
 
Figure 2 Ectopic expression of GPR39 or preproghrelin/GPR39 enhances muscle 
regeneration. (a) Left panel, fluorescence microscopy of GFP (pcDNA 3.1-SNAP-GFP, 
transfection marker) and immunofluorescence analysis of cryosections stained with antibodies 
reactive to laminin and GPR39 168-h after electroporation with the CMV-GPR39 plasmid. 
Middle panel, representative immunoblots of the mean values from each group of the 
expression of Pax-7, MyoD, myogenin, and eMHC at 96- and 168-h after ectopic expression of 
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GPR39. Right panel, immunoblot analysis of the expression of Pax-7, MyoD, myogenin, and 
MHC at 96- and 168-h after ectopic expression of GPR39. (b) Left panel, fluorescence 
microscopy of GFP (pcDNA 3.1-SNAP-GFP, transfection marker) and immunofluorescence 
analysis of the cryosections stained with antibodies reactive to laminin, preproghrelin or 
GPR39 168-h after electroporation with both CMV-GPR39 and CMV-preproghrelin plasmids. 
Right panel, representative immunoblots of the mean values from each group of the 
expression of Pax-7, MyoD, myogenin, and MHC at 96- and 168-h after ectopic expression of 
GPR39. Bottom panel, immunoblot analysis of the expression of Pax-7, MyoD, myogenin, and 
eMHC at 96- and 168-h after ectopic expression of GPR39 and preproghrelin. For a and b, 
protein levels were expressed as fold of control obtained from electroporation of CMV plasmid 
group (n=5/group). Data were expressed as mean±SEM obtained from intensity scans. *P 
<0.05 versus control values. 
 
Figure 3 Intramuscular obestatin administration enhances muscle regeneration. (a) 
Upper panel, immunofluorescence analysis of the obestatin dispersion in the distal zone from 
the injection site [obestatin-HA: 300 nmol/kg body weight; 30 min after administration]. Lower 
panel, immunofluorescence analysis of pAkt(S473) of distal cross-sections of obestatin-HA-
injected TA, contralateral TA and control TA muscles. Cryosections were stained with 
antibodies reactive to HA-tag, laminin, pAkt(S473) and counterstained with DAPI 30-min after 
injection of HA-obestatin. (b) Representative images of hematoxylin/eosin-stained sections of 
resting (control) and freeze-injured TA muscles after intramuscular injection of obestatin [300 
nmol/kg body weight/24-h during 5 days; n=5 per time point] or vehicle (PBS) at 48-, 96-, 168- 
and 240-h following injury. (c) Effect of intramuscular injection of obestatin [300 nmol/kg body 
weight/24 h] on regenerating myofiber (centrally located nuclei) cross-section area at 96 and 
168 hours following injury. (d) Cross-sectional area measurements of freeze-injured TA 
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muscles after intramuscular injection of obestatin [300 nmol/kg body weight/24-h during 5 
days; n=5 per group] at 240 hours following injury. (e) Representative immunoblots of the 
mean values from each group of the expression of Pax-7, MyoD, myogenin, and eMHC in 
freeze-injured TA muscles after intramuscular injection of obestatin or vehicle (PBS) at 48-, 96-
, 168- and 240-h following injury. (e-i) Immunoblot analysis of the expression of Pax-7 (f), 
MyoD (g), myogenin (h), and eMHC (i) in resting (control) and freeze-injured TA muscles after 
intramuscular injection of obestatin [300 nmol/kg body weight/24-h during 5 days; n=5 per time 
point] or vehicle (PBS) at 48-, 96-, 168- and 240-h following injury. Protein levels were 
expressed as fold of control (n=5/group). Data were expressed as mean±SEM obtained from 
intensity scans. *,# P<0.05 versus control values. (j) Representative immunofluorescence 
images of eMHC in freeze-injured TA muscles after intramuscular injection of obestatin [300 
nmol/kg body weight/24-h during 5 days; n=5 per time point] or vehicle (PBS) at 96-h following 
injury. (k) Serum creatine kinase (CK) levels at 96-h post-injury (n=15 per group). Results are * 
P <0.05 versus control values. 
 
Figure 4 Obestatin activates SCs and increases the number of nuclei per muscle fiber. 
(a) Average number of myonuclei per 100 TA muscle fibers after intramuscular injection of 
obestatin [300 nmol/kg body weight/24h during 5 days; n=5 per group] or control (PBS) at 240 
hours following injury (n=5 per group). (b) Sample section for Pax7 and laminin in freeze-
injured TA muscle after intramuscular injection of obestatin [300 nmol/kg body weight/24-h 
during 5 days; n=5 per group] or control (PBS) at 96-h following injury (left panel). 
Colocalization of Pax7 and DAPI staining from boxed region is shown in the middle panel. The 
analysis of the relative satellite cell density (ratio of satellite cell number to the cross-section 
area and normalized to the ratio in control muscles) is shown at 96-h following injury. Results 
were calculated from the average values of 3 muscle sections per mouse, and 5 mice were 
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analyzed (right panel). (c) Left panel, immunofluorescence analysis of Pax7 positive satellite 
cells (Pax7+) in myofibers isolated from the neighboring area of the injured zone of the TA 
muscle after intramuscular injection of obestatin [300 nmol/kg body weight/24h during 5 days; 
n=5 per group] or control (PBS) at 96-h following injury. Right panel, Pax7+ cells were 
enumerated and normalized against myofiber length (µm). Results were calculated from 
average values of 12 isolated myofibers per mouse, and 5 mice were analyzed per group 
(n=60 per group). Data were expressed as mean±SEM. * P <0.05 versus control values. 
 
Figure 5 Effect of obestatin administration on muscle force. Obestatin or PBS (vehicle) 
was administrated via intramuscular injection in freeze-injured TA muscle (300 nmol/kg body 
weight/24h during 5 days). Uninjured TA muscles were taken as control to establish that the 
damage area was large enough to decrease force (n=6 per group). Muscle force 
measurements were assessed after an interval of 5 days after the last dose. (a) Effect of 
intramuscular injection of obestatin on twitch force at 240 h following injury. (b) Effect of 
intramuscular injection of obestatin on tetanic force at 240 h following injury.  (c) Force-
frequency curve of TA muscles in control and obestatin- or PBS-treated groups. Data in (a-c) 
were expressed as mean±SEM. *P<0.05 versus control values.  
 
Figure 6 Obestatin regulates the regenerative microenvironment responsible for 
stimulating and coordinating skeletal muscle repair. Effect of intramuscular injection 
obestatin [300 nmol/kg body weight/24h during 5 days; n=5 per group] or control (PBS) in 
freeze-injured TA muscle on Ki67 (a), Cyclin D1 (b), VEGF (c), VEGF-R2 (d), average number 
of isolectin positive vessels (isolectin+) (e), Col1a2 (f), and myostatin (g) at 96 or 240 hours 
following injury. Analysis of the expression of Ki67, Cyclin D1, VEGF, VEGF-R2, Col1a2 and 
myostatin were performed by immunoblot and protein levels were expressed as fold of control 
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(n=5 per group). Immunoblots are representative of mean values from each group. Data were 
expressed as mean±SEM obtained from intensity scans. Isolectin positive vessels were 
analyzed by immunofluorescence of cryosections stained with isolectin, laminin and 
counterstained with DAPI. Representative images of the mean values from each group are 
shown in the upper panel from (e). Representative images of the histological analysis from 
sections stained with Heidenhain's AZAN trichrome staining are shown in the bottom panel 
from (f). *P <0.05 versus control values. 
 
Figure 7 Obestatin effect on cell proliferation. (a) Dose-response effect of obestatin (0.01-
100 nM) on C2C12 myoblast cell proliferation (48 h, n=5). Co: cells initially seeded. Control: 
cells maintained 48 h in GM. (b) Immunoblot analysis of Ki67, p57, p21, myogenin, and MHC 
expression in the course of C2C12 myogenesis under DM or DM+obestatin (5 nM). Protein 
level was expressed as fold of control cells in GM (n=3). Immunoblots are representative of the 
mean value. Data were expressed as mean±SEM obtained from intensity scans. * P <0.05 
versus control values. 
 
Figure 8 The hypertrophic response to obestatin is not associated with the addition of 
new myonuclei via proliferation and further fusion. (a) Left panel, immunofluorescence 
detection of MHC and DAPI in C2C12 myotube cells under DM (control) or DM+obestatin (5 
nM) at the 7-day point after stimulation. Right panel, the myotube area (µm2) and the number 
of nuclei within individual myotubes (at least two nuclei) were evaluated. (b) Left panel, 
immunofluorescence detection of MHC and DAPI in C2C12 myotube cells under DM (control) 
or DM+obestatin (5 nM; 3 days of differentiation) at the 7-day point after stimulation. Right 
panel, the myotube area (µm2) and the number of nuclei within individual myotubes were 
evaluated. (c) Left panel, immunofluorescence detection of MHC and DAPI in C2C12 myotube 
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cells at 7-day point after stimulation under DM (control) or DM+obestatin (5 nM)+AraC (50 µM) 
applied at day three of differentiation. Right panel, the myotube area (µm2) and the number of 
nuclei within individual myotubes (at least two nuclei) were evaluated. (d) Immunoblot analysis 
of myogenin, and MHC expression in C2C12 myotubes at the 7-day point after stimulation 
under AraC treatment as indicated in (c). Immunoblots are representative of mean values from 
each group. Data were expressed as mean±SEM obtained from intensity scans. * P <0.05 
versus control values. 
 
Figure 9 Obestatin-activated intercellular networks involved during myogenic program 
in C2C12 cells. (a) Immunoblot analysis of pAkt(S473), pERK1/2(T202/Y204), 
pp38(T180/Y182), pS6K1(S6371), pFoxO1(T24)/FoxO3a(T32), pCAMKII(T286), and, pc-
Jun(S63) in the course of C2C12 myogenesis under DM or DM+obestatin (5 nM). (b) 
Immunoblot analysis of pIGFR(Y1316) and pIRS1(S636/639) in the course of C2C12 
myogenesis under DM or DM+obestatin (5 nM). For (a) and (b), protein level was expressed 
as fold of control cells in GM (n=5). Immunoblots are representative of the mean value. Data 
were expressed as mean± SEM obtained from intensity scans. * P <0.05 versus control 
values. 
 
Figure 10 Obestatin-activated intercellular networks involved during myogenic program 
in TA muscle 96-h following injury. (a) Immunoblot analysis of pAkt(S473), 
pERK1/2(T202/Y204), pp38(T180/Y182), pS6K1(S6371), pFoxO1(T24)/FoxO3a(T32), 
pCAMKII(T286), and, pc-Jun(S63) in freeze-injured TA muscles after intramuscular injection of 
obestatin [300 nmol/kg body weight/24-h during 5 days; n=5] or vehicle (PBS) at 96 hours 
following injury. (b) Immunoblot analysis of pIGFR(Y1316) and pIRS1(S636/639) in freeze-
injured TA muscles after intramuscular injection of obestatin [300 nmol/kg body weight/24h 
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during 5 days; n=5] or vehicle (PBS) at 96 hours following injury. For (a) and (b), protein level 
was expressed as fold of control TA muscle (n=5 per group). Immunoblots are representative 
of the mean value. Data were expressed as mean±SEM obtained from intensity scans. * P 
<0.05 versus control values. 
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